VANGUARD GROUP INC - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 162 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2021. The put-call ratio across all filers is 0.67 and the average weighting 0.4%.

Quarter-by-quarter ownership
VANGUARD GROUP INC ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q3 2023$72,061,230
-18.2%
2,618,504
+0.8%
0.00%0.0%
Q2 2023$88,143,897
-3.9%
2,597,816
+1.9%
0.00%0.0%
Q1 2023$91,698,556
-18.1%
2,548,598
+1.4%
0.00%
-33.3%
Q4 2022$112,029,548
+61.0%
2,513,564
+1.5%
0.00%
+50.0%
Q3 2022$69,583,000
+6.0%
2,475,381
+1.6%
0.00%0.0%
Q2 2022$65,659,000
-20.8%
2,435,372
+0.1%
0.00%0.0%
Q1 2022$82,889,000
-11.1%
2,433,595
+0.9%
0.00%0.0%
Q4 2021$93,240,000
-24.1%
2,413,056
+6.0%
0.00%
-33.3%
Q3 2021$122,892,000
+86.5%
2,276,199
+15.5%
0.00%
+50.0%
Q2 2021$65,889,000
+77.9%
1,970,406
+9.6%
0.00%
+100.0%
Q1 2021$37,046,000
+19.6%
1,798,327
+1.7%
0.00%0.0%
Q4 2020$30,973,000
+21.2%
1,767,915
+2.6%
0.00%0.0%
Q3 2020$25,557,000
+51.7%
1,723,317
+33.0%
0.00%0.0%
Q2 2020$16,851,000
+1787.0%
1,296,206
+141.0%
0.00%
Q1 2020$893,000
-22.4%
537,928
+4.2%
0.00%
Q4 2019$1,151,000
+4.7%
516,1180.0%0.00%
Q3 2019$1,099,000
+37.4%
516,118
+72.8%
0.00%
Q2 2019$800,000
-66.7%
298,674
-38.8%
0.00%
Q1 2019$2,402,000488,2360.00%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q3 2021
NameSharesValueWeighting ↓
Kynam Capital Management, LP 2,600,000$88,218,00012.13%
Octagon Capital Advisors LP 759,898$25,783,3393.59%
TSP Capital Management Group, LLC 251,895$8,546,8003.08%
ACUTA CAPITAL PARTNERS, LLC 122,343$4,151,0982.81%
5AM Venture Management, LLC 310,270$10,527,4612.62%
COMMODORE CAPITAL LP 631,665$21,432,3932.41%
RTW INVESTMENTS, LP 3,463,201$117,506,4102.24%
Eversept Partners, LP 785,740$26,660,1582.23%
Redmile Group, LLC 1,696,004$57,545,4162.21%
Affinity Asset Advisors, LLC 87,031$2,952,9621.03%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders